子痫前期profin -1水平：与疾病和不良新生儿结局的关系

IF 3 2区医学 Q2 DEVELOPMENTAL BIOLOGY

Placenta Pub Date : 2025-01-01 DOI:10.1016/j.placenta.2024.12.012

Sadullah Özkan , Alperen Aksan , Fahri B. Fıratlıgil , Dilara Kurt , Serap Sucu , Aslıhan Coşkun , Kadriye Yakut Yücel , A. Turhan Çağlar , Yaprak Engin Üstün

{"title":"子痫前期profin -1水平：与疾病和不良新生儿结局的关系","authors":"Sadullah Özkan , Alperen Aksan , Fahri B. Fıratlıgil , Dilara Kurt , Serap Sucu , Aslıhan Coşkun , Kadriye Yakut Yücel , A. Turhan Çağlar , Yaprak Engin Üstün","doi":"10.1016/j.placenta.2024.12.012","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Preeclampsia is a serious pregnancy complication requiring early detection to improve outcomes. Profilin-1 (PFN1), linked to vascular dysfunction, may serve as a biomarker for diagnosing preeclampsia and predicting adverse neonatal outcomes. The aim of this study was to determine the serum Profilin-1 levels in patients diagnosed with preeclampsia and to investigate its association with disease severity and adverse neonatal outcomes.</div></div><div><h3>Methods</h3><div>A prospective cross-sectional study was conducted at Etlik City Hospital involving 40 women with preeclampsia and 40 healthy controls. Serum PFN1 levels were measured by ELISA and results were compared between groups. The results were compared between the groups. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance of PFN1.</div></div><div><h3>Results</h3><div>Serum PFN1 levels were significantly higher in the preeclampsia group compared to controls (46.48 [30.23–60.29] vs. 26.41 [19.65–41.76], p < 0.001). The ROC curve showed good diagnostic accuracy for PFN1 in detecting preeclampsia with an AUC of 0.741 (95 % CI: 0.631–0.832, p < 0.001), a sensitivity of 95 % and a specificity of 42.5 %. PFN1 levels were also associated with composite neonatal outcomes, with an AUC of 0.622 (95 % CI: 0.520–0.716, p = 0.042).</div></div><div><h3>Discussion</h3><div>PFN1 is a potential biomarker for the diagnosis of preeclampsia. However, further studies are needed to validate its role in predicting adverse neonatal outcomes and to improve its specificity for clinical use.</div></div>","PeriodicalId":20203,"journal":{"name":"Placenta","volume":"159 ","pages":"Pages 140-145"},"PeriodicalIF":3.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Profilin-1 levels in preeclampsia: Associations with disease and adverse neonatal outcomes\",\"authors\":\"Sadullah Özkan , Alperen Aksan , Fahri B. Fıratlıgil , Dilara Kurt , Serap Sucu , Aslıhan Coşkun , Kadriye Yakut Yücel , A. Turhan Çağlar , Yaprak Engin Üstün\",\"doi\":\"10.1016/j.placenta.2024.12.012\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Preeclampsia is a serious pregnancy complication requiring early detection to improve outcomes. Profilin-1 (PFN1), linked to vascular dysfunction, may serve as a biomarker for diagnosing preeclampsia and predicting adverse neonatal outcomes. The aim of this study was to determine the serum Profilin-1 levels in patients diagnosed with preeclampsia and to investigate its association with disease severity and adverse neonatal outcomes.</div></div><div><h3>Methods</h3><div>A prospective cross-sectional study was conducted at Etlik City Hospital involving 40 women with preeclampsia and 40 healthy controls. Serum PFN1 levels were measured by ELISA and results were compared between groups. The results were compared between the groups. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance of PFN1.</div></div><div><h3>Results</h3><div>Serum PFN1 levels were significantly higher in the preeclampsia group compared to controls (46.48 [30.23–60.29] vs. 26.41 [19.65–41.76], p < 0.001). The ROC curve showed good diagnostic accuracy for PFN1 in detecting preeclampsia with an AUC of 0.741 (95 % CI: 0.631–0.832, p < 0.001), a sensitivity of 95 % and a specificity of 42.5 %. PFN1 levels were also associated with composite neonatal outcomes, with an AUC of 0.622 (95 % CI: 0.520–0.716, p = 0.042).</div></div><div><h3>Discussion</h3><div>PFN1 is a potential biomarker for the diagnosis of preeclampsia. However, further studies are needed to validate its role in predicting adverse neonatal outcomes and to improve its specificity for clinical use.</div></div>\",\"PeriodicalId\":20203,\"journal\":{\"name\":\"Placenta\",\"volume\":\"159 \",\"pages\":\"Pages 140-145\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Placenta\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0143400424008038\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DEVELOPMENTAL BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Placenta","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0143400424008038","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DEVELOPMENTAL BIOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

背景：子痫前期是一种严重的妊娠并发症，需要早期发现以改善结局。Profilin-1 （PFN1）与血管功能障碍有关，可作为诊断子痫前期和预测新生儿不良结局的生物标志物。本研究的目的是确定诊断为子痫前期患者的血清Profilin-1水平，并探讨其与疾病严重程度和不良新生儿结局的关系。方法：在Etlik市医院进行了一项前瞻性横断面研究，涉及40名先兆子痫妇女和40名健康对照。采用ELISA法测定血清PFN1水平，并比较各组间结果。结果在两组之间进行比较。采用受试者工作特征（ROC）曲线评价PFN1的诊断效能。结果：与对照组相比，子痫前期组血清PFN1水平显著升高(46.48[30.23-60.29]对26.41 [19.65-41.76]，p讨论：PFN1是诊断子痫前期的潜在生物标志物。然而，需要进一步的研究来验证其在预测新生儿不良结局中的作用，并提高其临床应用的特异性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Profilin-1 levels in preeclampsia: Associations with disease and adverse neonatal outcomes

Background

Preeclampsia is a serious pregnancy complication requiring early detection to improve outcomes. Profilin-1 (PFN1), linked to vascular dysfunction, may serve as a biomarker for diagnosing preeclampsia and predicting adverse neonatal outcomes. The aim of this study was to determine the serum Profilin-1 levels in patients diagnosed with preeclampsia and to investigate its association with disease severity and adverse neonatal outcomes.

Methods

A prospective cross-sectional study was conducted at Etlik City Hospital involving 40 women with preeclampsia and 40 healthy controls. Serum PFN1 levels were measured by ELISA and results were compared between groups. The results were compared between the groups. Receiver operating characteristic (ROC) curves were used to evaluate the diagnostic performance of PFN1.

Results

Serum PFN1 levels were significantly higher in the preeclampsia group compared to controls (46.48 [30.23–60.29] vs. 26.41 [19.65–41.76], p < 0.001). The ROC curve showed good diagnostic accuracy for PFN1 in detecting preeclampsia with an AUC of 0.741 (95 % CI: 0.631–0.832, p < 0.001), a sensitivity of 95 % and a specificity of 42.5 %. PFN1 levels were also associated with composite neonatal outcomes, with an AUC of 0.622 (95 % CI: 0.520–0.716, p = 0.042).

Discussion

PFN1 is a potential biomarker for the diagnosis of preeclampsia. However, further studies are needed to validate its role in predicting adverse neonatal outcomes and to improve its specificity for clinical use.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Placenta 医学-发育生物学

CiteScore

6.30

自引率

10.50%

发文量

391

审稿时长

78 days

期刊介绍： Placenta publishes high-quality original articles and invited topical reviews on all aspects of human and animal placentation, and the interactions between the mother, the placenta and fetal development. Topics covered include evolution, development, genetics and epigenetics, stem cells, metabolism, transport, immunology, pathology, pharmacology, cell and molecular biology, and developmental programming. The Editors welcome studies on implantation and the endometrium, comparative placentation, the uterine and umbilical circulations, the relationship between fetal and placental development, clinical aspects of altered placental development or function, the placental membranes, the influence of paternal factors on placental development or function, and the assessment of biomarkers of placental disorders.